Marc Horn, Ph.D. – Co-Founder and Chief Executive Officer

• Over 35 years of experience in biochemistry and biotech
• Has developed and patented over 20 technologies in biochemistry and biotechnology
• Founded and successfully brought four companies from concept to commercialization to exit prior to founding Prospect Biosystems. First two companies (Sequemat, Inc. and Genetic Design, Inc.) were founded while he was in graduate school and were subsequently sold to Millipore Corp (now Merck KGaA); the third, Applied Protein Technologies, was sold to Hewlett-Packard (now Agilent Technologies); and the fourth, Bimolecular Technologies, Inc., was sold to Amersham-Pharmacia (now GE Healthcare)
• The first President of Alfa Wassermann Proteomic Technologies (a subsidiary of Alfa Wasserman, Inc.). Headed Protein Chemistry Systems, a division of Hewlett Packard’s Analytical Product Group (now Agilent Technologies)
• Post-doctoral fellowship at Harvard Medical School

Wendy Lan, Ph.D. – Co-Founder and Chief Technology Officer

• Over 20 years of experience in biochemistry and the diagnostic/pharmaceutical industry
• Director of Research Application at Alfa Wasserman Proteomic Technologies and Biomolecular Technologies
• Principal Research Scientist at Hoffman La Roche
• Developed analytical methods for diagnostics and pharmaceutical development, and managed the development and commercialization of several bioanalytical applications for the biotechnology and pharmaceutical industry.
• Post-doctoral fellowship at the University of California, Berkeley

Win Troung - Chief Financial Officer

• Joined Prospect Biosystems in late 2008
• Over 13 years of business, financial and investment banking experience
• Director of Investments and Chief Operating Officer at Millennium Asset Management, a firm specializing in strategic and alternative growth investments for institutional investors
• Has served as director and strategic advisor to several start-up companies in the United States and Asia
• Graduate of Harvard University